Overview
Liming Lin practices practicing medicine in Putian, China.
Their clinical expertise encompasses Doxorubicin-Induced Cardiomyopathy, Heart Failure with Preserved Ejection Fraction (HFpEF), Cardiomyopathy Due to Anthracyclines, and Squamous Cell Lung Carcinoma.
They are actively involved in clinical research, co-authoring 18 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Liming Lin
Is Liming Lin a top-rated expert for Doxorubicin-Induced Cardiomyopathy?
MediFind is an objective health platform that identifies experts based on real-world data. Liming Lin is classified as an Experienced expert for Doxorubicin-Induced Cardiomyopathy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Liming Lin participate in research or clinical trials?
Yes. Liming Lin has published 18 articles and abstracts on conditions like Doxorubicin-Induced Cardiomyopathy. You can view a list of Liming Lin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Cardiomyopathy Due to Anthracyclines
- Doxorubicin-Induced Cardiomyopathy
- Heart FailureLin isExperienced. Learn about Heart Failure.
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Squamous Cell Lung Carcinoma